164 Correlations between etiopathogenic factors and persistence of anti-IL-17A biologic therapies in patients with severe psoriasis vulgaris

In recent years, multiple biologic therapies with various mechanisms of action for the treatment inflammatory diseases have been developed, including moderate to severe plaque psoriasis. The choice optimal psoriasis can depend on several factors and is strongly influenced by effectiveness safety profile a drug. Thus, following an observational, non-interventional, retrospective study patients receiving biological IL-17 inhibitors, we analyzed our experience in evaluating from real data persistence anti-IL-17A identify that may affect these patients. Our results provide unbiased true analysis outcome agents. Biological prescribed exacerbate comorbidities, which turn influence Therefore, proper management should involve integrated approach. interact each other directly / or indirectly pathogenesis For example, obesity, female gender, existence psoriatic arthritis are associated course also patient’s age, lifestyle, concomitant illness. Patients’ affects rates therapies, this help both clinicians make decisions. holistic approach patient placing it at center concerns as therapists generally valid always relevant goals trying reduce burden